BIIB059

Phase 3Small molecule

Biogen

BIIB059 is one of 67 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Subacute Cutaneous Lupus ErythematosusEnrolling by invitation

Cutaneous Lupus ErythematosusActive, not recruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Subacute Cutaneous Lupus ErythematosusPhase 3

Enrolling by invitation

Cutaneous Lupus ErythematosusPhase 2

Active, not recruiting

Competition

Competitive Landscape

328 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

9 2

Rinvoq

AbbVie

Phase 3

3 3

Stelara

Johnson & Johnson

Phase 3

3 4

Gazyva

Roche

Phase 3

2 5

Ocrevus

Roche

Phase 3

2 6

Intrarosa

Alnylam Pharmaceuticals

Phase 3

1 7

Rayos

RRoxane Laboratories

Phase 3

6 8

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

3 9

Benadryl

PParkedale

Phase 3

3 10

Tylenol

KKenvue Brands

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Single Dose1 trial

Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects.

Completed· Biogen logo

Biogen·Phase 1·NCT03224793·32 enrolled

Cutaneous Lupus Erythematosus1 trial

Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)

Completed· Biogen logo

Biogen·Phase 2·NCT02847598·264 enrolled

Systemic Lupus Erythematosus1 trial

Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus

Completed· Biogen logo

Biogen·Phase 1·NCT02106897·109 enrolled

Subacute Cutaneous Lupus Erythematosus1 trial

A Multicenter, Open-Label, Single-Arm, Phase 3, Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adult Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy

Enrolling by invitation· Biogen logo

Biogen·Phase 3·NCT06044337·306 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for BIIB059. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BIIB059 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BIIB059. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biogen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Biogen

BIIB059

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Single Dose1 trial

Cutaneous Lupus Erythematosus1 trial

Systemic Lupus Erythematosus1 trial

Subacute Cutaneous Lupus Erythematosus1 trial

References

Drug Info

Quick Facts

Related News